Murray NP - Search Results

1

[Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].

Murray NP, Aedo S, Fuentealba C, Reyes E, Minzer S, Salazar A. Murray NP, et al. Arch Esp Urol. 2019 Jun;72(5):471-482. Arch Esp Urol. 2019. PMID: 31223125 Free article. Spanish.

2

Presence of prostate cells in bone marrow biopsies as a sign of micrometastasis in cancer patients.

Murray NP, Calaf GM, Badínez L. Murray NP, et al. Oncol Rep. 2009 Mar;21(3):571-5. Oncol Rep. 2009. PMID: 19212613

3

Detection and characteristics of primary circulating prostate cells; association with micrometastasis and implications for surgical treatment of men with prostate cancer.

Murray NP, Reyes E, Badínez L, Orellana N, Dueñas R, Fuentealba C. Murray NP, et al. Arch Esp Urol. 2010 Jun;63(5):345-53. Arch Esp Urol. 2010. PMID: 20587839 English, Spanish.

4

P504S expressing circulating prostate cells as a marker for prostate cancer.

Murray NP, Calaf GM, Badinez L, Dueñas R, Badinez O, Orellana N, Reyes E, Fuentealba C. Murray NP, et al. Oncol Rep. 2010 Sep;24(3):687-92. doi: 10.3892/or_00000908. Oncol Rep. 2010. PMID: 20664974

5

Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.

Murray NP, Reyes E, Tapia P, Orellana N, Dueñas R, Fuentealba C, Badinez L. Murray NP, et al. Arch Esp Urol. 2011 Dec;64(10):961-71. Arch Esp Urol. 2011. PMID: 22228894 English, Spanish.

6

Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy.

Murray NP, Reyes E, Tapia P, Badinez L, Orellana N, Fuentealba C, Olivares R, Porcell J, Dueñas R. Murray NP, et al. Int J Mol Med. 2012 Oct;30(4):896-904. doi: 10.3892/ijmm.2012.1071. Epub 2012 Jul 20. Int J Mol Med. 2012. PMID: 22825050

7

Hypernephroma presenting with cutaneous leukocytoclastic vasculitis and lupus anticoagulant: resolution after nephrectomy.

Murray NP, Ruíz A, Reyes E. Murray NP, et al. Case Rep Urol. 2012;2012:108230. doi: 10.1155/2012/108230. Epub 2012 Aug 7. Case Rep Urol. 2012. PMID: 22919534 Free PMC article.

8

Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an immunocytochemical study.

Murray NP, Reyes E, Tapia P, Badínez L, Orellana N. Murray NP, et al. Bone Marrow Res. 2012;2012:259351. doi: 10.1155/2012/259351. Epub 2012 Nov 26. Bone Marrow Res. 2012. PMID: 23227342 Free PMC article.

9

Cost-Benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer.

Murray NP, Reyes E, Orellana N, Tapía P. Murray NP, et al. Arch Esp Urol. 2013 Apr;66(3):277-86. Arch Esp Urol. 2013. PMID: 23648747 English, Spanish.

10

Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease.

Murray NP, Reyes E, Orellana N, Fuentealba C, Bádinez L, Olivares R, Porcell J, Dueñas R. Murray NP, et al. ScientificWorldJournal. 2013 Mar 31;2013:762064. doi: 10.1155/2013/762064. Print 2013. ScientificWorldJournal. 2013. PMID: 23653529 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

110 results

Search Page

Filters